Moreover, the FDA has already approved the use of commercial GFAP assays for screening of brain trauma/concussions, and similar proteomic assays (e.g. serum NfL levels) are currently being reviewed for their use in multiple sclerosis disease monitoring. This evidence concerns the gene GFAP and multiple sclerosis.